Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy.
Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy.
复制标题
Q151M 介导的多核苷耐药性：患病率、危险因素和挽救治疗的反应。
DOI：
10.1086/381097
复制
发表时间：
2004
期刊：
影响因子：
--
通讯作者：
A. Antinori
中科院分区：
文献类型：
--
作者：
M. Zaccarelli;C. Perno;F. Forbici;F. Soldani;S. Bonfigli;C. Gori;M. Trotta;M. Bellocchi;G. Liuzzi;R. D'arrigo;P. De Longis;E. Boumis;R. Bellagamba;V. Tozzi;P. Narciso;A. Antinori
在 470 名治疗失败后接受基因型耐药性检测（GRT）的获得性免疫缺陷综合征和/或人类免疫缺陷病毒感染（HIV/AIDS）患者中，17 例（3.6%）携带 Q151M 突变。 Q151M 突变与年龄较小、CD4(+) 淋巴细胞计数较低、HIV RNA 水平较高以及使用 >2 种 GRT 前方案治疗相关。相比之下，Q151M 突变与拉米夫定给药呈负相关。在 GRT 后接受治疗中断的 5 名患者中，有 5 名观察到 Q151M 突变完全逆转。 5 名患者中有 4 名（80%）在病情逆转后对挽救治疗产生了反应。
Among 470 patients with acquired immune deficiency syndrome and/or human immunodeficiency virus infection (HIV/AIDS) who underwent genotype resistance testing (GRT) after the failure of therapy, 17 (3.6%) harbored the Q151M mutation. The Q151M mutation was associated with younger age, lower CD4(+) lymphocyte count, higher HIV RNA level, and treatment with >2 pre-GRT regimens. By contrast, the Q151M mutation was inversely associated with lamivudine administration. A full reversion of the Q151M mutation was observed in 5 of 5 patients who underwent treatment interruption after GRT. The reversion was followed by a response to salvage therapy in 4 (80%) of 5 patients.